Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | FASN | P49327 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3550415 | 1.00 | RECQL (0.56) | RECQLALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL3122976 | 1.00 | RECQL (0.56) | RECQLALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL12489672 | 0.85 | RECQL (0.63) | RECQLALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL28312550 | 0.85 | RECQL (0.63) | RECQLALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL11969437 | 0.83 | RECQL (0.61) | RECQLALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL1372881 | 0.80 | RECQL (0.62) | RECQLALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL28313549 | 0.79 | RECQL (0.57) | RECQLALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL20178173 | 0.79 | RECQL (0.57) | RECQLALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL5423821 | 0.79 | RECQL (0.56) | RECQLALDH1A1KDM4ETSHRHSD17B10 | |
| SCHEMBL1021697 | 0.79 | RECQL (0.56) | RECQLALDH1A1KDM4ETSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003664-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2011-08-23 | — | — | US | claimed |
| US-20100292223-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2010-11-18 | — | — | US | claimed |
| US-7786136-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2010-08-31 | — | — | US | claimed |
| EP-1831211-B1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2010-06-02 | — | — | EP | claimed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20080132491-A1 | Indazole-carboxamide compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-05 | — | — | US | claimed |
| EP-1831211-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | Theravance, Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006069125-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2006-06-29 | — | — | WO | claimed |
| US-20060135764-A1 | Indazole-carboxamide compounds | THERAVANCE, INC. | 2006-06-22 | — | — | US | claimed |
| US-4987133-A | Salicylic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1991-01-22 | — | — | US | claimed |
| EP-0338352-A2 | Salicylic acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-25 | — | — | EP | claimed |
| EP-2029551-B1 | PYRIDINONE AND PYRIDAZINONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | MSD ITALIA SRL (IT) | 2018-10-31 | — | — | EP | disclosed |
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-8222414-B2 | Indole compounds as an inhibitor of cellular necrosis | LG LIFE SCIENCES LTD. (KR) | 2012-07-17 | — | — | US | disclosed |
| US-8188084-B2 | Pyridinone and pyridazinone derivatives as inhibitors of poly (ADP-ribose) polymerase (PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. (IT) | 2012-05-29 | — | — | US | disclosed |
| US-4987133-A | Salicylic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1991-01-22 | — | — | US | disclosed |
| US-4987133-A | Salicylic acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1991-01-22 | — | — | US | disclosed |
| EP-0338352-A3 | SALICYLIC ACID DERIVATIVES | MERCK PATENT GmbH (DE) | 1990-03-14 | — | — | EP | disclosed |
| EP-0338352-A2 | Salicylic acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-25 | — | — | EP | disclosed |
| EP-0338352-A2 | Salicylic acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292223-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | HTR4, HTR5A, HTR3B | RECQL 4048/4885ALDH1A1 1634/4885KDM4E 1283/4885 |
| US-20080132491-A1 | Indazole-carboxamide compounds | HTR4, HTR5A, HTR3B | RECQL 4048/4885ALDH1A1 1634/4885KDM4E 1283/4885 |
| US-20060135764-A1 | Indazole-carboxamide compounds | HTR4, HTR5A, HTR3B | RECQL 4048/4885ALDH1A1 1634/4885KDM4E 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.